Viewed altogether, the findings from this exploratory clinical study suggest that early monitoring of two key predictors of lung abnormalities, namely, circulating levels of CRP and albumin, may permit early therapeutic interventions to avoid or limit COVID-19 progression. This evidence concerns the gene CRP and COVID-19.